AZD-7687

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H25N3O3
Molecular Weight	367.4415
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC(C)=C(N=C1C2=CC=C(C=C2)[C@H]3CC[C@H](CC(O)=O)CC3)C(N)=O

InChI

InChIKey=YXFNPRHZMOGREC-SHTZXODSSA-N

InChI=1S/C21H25N3O3/c1-12-19(24-20(21(22)27)13(2)23-12)17-9-7-16(8-10-17)15-5-3-14(4-6-15)11-18(25)26/h7-10,14-15H,3-6,11H2,1-2H3,(H2,22,27)(H,25,26)/t14-,15-

HIDE SMILES / InChI

Molecular Formula	C21H25N3O3
Molecular Weight	367.4415
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23116186 | https://www.ncbi.nlm.nih.gov/pubmed/24118885

AZD-7687 is a potent inhibitor of Diacylglycerol O-acyltransferase 1 (DGAT1) which was developed by AstraZeneca for the treatment obesity and type 2 diabetes mellitus. AZD-7687 reached phase I of clinical trials, but was discontinued by unknown reasons.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Diacylglycerol O-acyltransferase 1 7 Target ID: O75907 Gene ID: 8694.0 Gene Symbol: DGAT1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23116186	Inhibitor 8297		0.08 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Obesity 203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22950654	Primary		Phase I 428	Unknown Approved Use Unknown
Type 2 diabetes mellitus 259 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22950654	Primary		Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
0.92 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
0.96 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
12 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
1.6 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
1.9 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
2.9 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
3.5 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT

AUC

Value	Dose	Analyte	Population
11 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
11 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
110 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
18 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
19 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
33 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: LOW-FAT
43 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22950654	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AZD-7687 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C19 1478 P-gp 1461	Human Hepatocytes 1

Drug as perpetrator

Target	Modality	Activity
P-gp 1650	inhibitor 3277 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363678240	inconclusive [IC50 20.5962 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23116186/	no [IC50 >30 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23116186/	no [IC50 >30 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23116186/	no [IC50 >30 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23116186/	no [IC50 >30 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23116186/	no [IC50 >30 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
Human Hepatocytes 1	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/23116186/	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/23116186/

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008TUG	https://www.1pchem.com/search?query=1P008TUG
Lan Pharmatech	LQT-B38840
MolPort	MolPort-046-702-037	https://www.molport.com/shop/molecule-link/MolPort-046-702-037
Norris Pharm	NSZB-A213763
eMolecules	195178693	https://orderbb.emolecules.com/search/#?query=195178693
eMolecules	300752917	https://orderbb.emolecules.com/search/#?query=300752917

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Multiple doses of AZD-7687 (1, 2.5, 5, 10 and 20 mg/day) were administered for 1 week.

Route of Administration: Oral

In Vitro Use Guide

Human adipose tissue was incubated with 200 uL of DMEM (6 mM glucose, 5% FCS, 0.5% penicillin/streptomycin) containing AZD-7687 dissolved in DMSO (0.1% final concentration) for 30 min at 37C, 5% CO2. AZD-7687 inhibited TAG synthesis in human adipose tissue with IC50 value of 0.01 uM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:35:18 UTC 2023` Edited by `admin` on `Sat Dec 16 05:35:18 UTC 2023`
Record UNII	6QTJ9P2NYT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-7687

Common Name

English

CYCLOHEXANEACETIC ACID, 4-(4-(6-(AMINOCARBONYL)-3,5-DIMETHYL-2-PYRAZINYL)PHENYL)-, TRANS-

Common Name

English

AZD7687

Code

English

AZD 7687 [WHO-DD]

Common Name

English

TRANS-4-(4-(6-(AMINOCARBONYL)-3,5-DIMETHYL-2-PYRAZINYL)PHENYL)CYCLOHEXANEACETIC ACID

Systematic Name

English

Code System Code Type Description

FDA UNII

6QTJ9P2NYT